MGEN - Miragen Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.8997
-0.0326 (-3.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.9323
Open0.9500
Bid0.8900 x 2200
Ask1.1000 x 1800
Day's Range0.8100 - 0.9500
52 Week Range0.6500 - 5.2500
Volume193,941
Avg. Volume249,507
Market Cap27.931M
Beta (3Y Monthly)1.80
PE Ratio (TTM)N/A
EPS (TTM)-1.2910
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth

    BOULDER, Colo., Oct. 16, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today new data from two Phase 1 clinical trials of MRG-110, miRagen’s microRNA-92 inhibitor, in which administration of MRG-110 was observed to increase angiogenesis, as demonstrated by increased perfusion and histological markers of neoangiogenesis, as well as reduce alpha-smooth muscle actin (α-SMA) expression, which has been show to correlate with activation of myofibroblasts. “We believe these Phase 1 safety, tolerability, pharmacokinetics, and biomarker data may provide mechanistic proof-of-concept for use of MRG-110 in the treatment of cardiovascular disease and certain other conditions where vascular flow is compromised,” said Paul Rubin, M.D., Executive Vice President, R&D, of miRagen Therapeutics.

  • GlobeNewswire

    miRagen Therapeutics to Present a Corporate Overview at the Robert W. Baird & Co. 2019 Global Healthcare Conference

    BOULDER, Colo., Aug. 15, 2019 -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a.

  • GlobeNewswire

    miRagen Therapeutics to Present a Corporate Overview at the 2019 Wedbush Healthcare Conference

    BOULDER, Colo., Aug. 12, 2019 -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a.

  • Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Tops Revenue Estimates

    Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 21.62% and 184.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    miRagen Reports Second Quarter 2019 Results; Regains Global Rights to MRG-110 and Announces Corporate Restructuring

    BOULDER, Colo., Aug. 07, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial results for the second quarter ended June 30, 2019 and provided a corporate update.

  • Analysts Estimate Signal Genetics, Inc. (MGEN) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Signal Genetics, Inc. (MGEN) to Report a Decline in Earnings: What to Look Out for

    Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Miragen Therapeutics to Report Second Quarter 2019 Financial Results and Host a Conference Call on August 7th

    BOULDER, Colo., July 24, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will host a conference call on Wednesday, August 7th, at 4:30 p.m. ET to discuss its financial results for the second quarter and six months ended June 30, 2019. The call will also be webcast and can be accessed from the Investors and Media section of the Company’s website at www.miragen.com.  A replay of this conference call will be available on miRagen’s website approximately one hour after the event.

  • Some Miragen Therapeutics (NASDAQ:MGEN) Shareholders Have Copped A Big 66% Share Price Drop
    Simply Wall St.

    Some Miragen Therapeutics (NASDAQ:MGEN) Shareholders Have Copped A Big 66% Share Price Drop

    The nature of investing is that you win some, and you lose some. And there's no doubt that Miragen Therapeutics, Inc...

  • GlobeNewswire

    miRagen Therapeutics to Present a Corporate Overview at the Jefferies 2019 Global Healthcare Conference

    BOULDER, Colo., May 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Jefferies 2019 Global Healthcare Conference, taking place June 4-7 in New York City.

  • GlobeNewswire

    miRagen Presents Preclinical Data in Pulmonary Fibrosis Using Second Generation microRNA-29 Replacement Product Candidate at the 2019 American Thoracic Society International Conference

    BOULDER, Colo., May 21, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it will report new data demonstrating that systemic administration of its second-generation microRNA-29 mimic, the Company’s pre-clinical micro-RNA targeted therapeutic candidate for idiopathic pulmonary fibrosis (“IPF”), efficiently reduced extracellular matrix deposition in a series of preclinical studies.  The data will be presented today at the 2019 American Thoracic Society (“ATS”) Conference in Dallas, TX. “We are encouraged by the data presented from several in vivo studies of our second-generation microRNA-29 mimic.  These data demonstrate efficacy in blunting the fibrotic response in the bleomycin model of pulmonary fibrosis in mice,” said Paul Rubin, M.D., Executive Vice President, R&D, of miRagen Therapeutics.

  • Signal Genetics, Inc. (MGEN) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    Signal Genetics, Inc. (MGEN) Reports Q1 Loss, Misses Revenue Estimates

    Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -8.57% and -72.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    miRagen Announces First Quarter 2019 Financial Results and Provides Corporate Update

    BOULDER, Colo., May 08, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial results for the first quarter ended March 31, 2019 and provided a corporate update. “Execution on our strategy by the miRagen team over the past few quarters has allowed us to make important advances in the development of cobomarsen, remlarsen, and MRG-110 in 2019, including initial dosing in the SOLAR Phase 2 trial of cobomarsen and the recent release of new data from our Phase 1 trial of cobomarsen in adult T-cell leukemia/lymphoma (ATLL) patients,” said William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen Therapeutics. “In addition to cobomarsen, we continue to make progress advancing remlarsen and MRG-110.  We look forward to releasing additional data from three clinical trials during the remainder of 2019, including our Phase 2 clinical trial of remlarsen in keloid scarring and two Phase 1 trials for MRG-110,” continued Dr. Marshall.

  • Earnings Preview: Signal Genetics, Inc. (MGEN) Q1 Earnings Expected to Decline
    Zacks

    Earnings Preview: Signal Genetics, Inc. (MGEN) Q1 Earnings Expected to Decline

    Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    miRagen Therapeutics Announces New Data Supporting the Potential Use of Remlarsen to Prevent Corneal Fibrosis at the 2019 ARVO Meeting

    Eyes were scored for corneal haze, then evaluated histologically for corneal thickness and expression of α-SMA (alpha smooth muscle actin), a marker of epithelial-to-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT). Expression of collagen and other fibrosis-associated genes was assessed using quantitative reverse transcription-polymerase chain reaction.

  • Can We See Significant Institutional Ownership On The Miragen Therapeutics, Inc. (NASDAQ:MGEN) Share Register?
    Simply Wall St.

    Can We See Significant Institutional Ownership On The Miragen Therapeutics, Inc. (NASDAQ:MGEN) Share Register?

    Every investor in Miragen Therapeutics, Inc. (NASDAQ:MGEN) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as s...

  • GlobeNewswire

    miRagen Announces New Clinical Data for Cobomarsen in ATLL Patients at the 19th Annual HTLV Congress in Lima, Peru

    BOULDER, Colo., April 26, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced incremental new data from its Phase 1 clinical trial evaluating the safety, tolerability and efficacy of cobomarsen, an inhibitor of microRNA-155, in adult T-cell leukemia/lymphoma (ATLL) in an oral presentation at the 19th International Congress HTLV 2019, which is being held from April 24 – 26, 2019, in Lima, Peru.

  • GlobeNewswire

    miRagen Therapeutics to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8th

    BOULDER, Colo., April 25, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, May 8th, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2019. A replay of this conference call will be available on miRagen’s website approximately one hour after the event.

  • GuruFocus.com

    Miragen Therapeutics Inc (MGEN) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Miragen Therapeutics Inc is a clinical-stage biopharmaceutical company which engaged in discovering and developing proprietary RNA (Ribonucleic acid)-targeted therapeutics. Miragen Therapeutics Inc had annual average EBITDA growth of 4.00% over the past five years. Warning! GuruFocus has detected 3 Warning Signs with MGEN.

  • Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Misses Revenue Estimates
    Zacks

    Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Misses Revenue Estimates

    Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -6.45% and -69.15%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    miRagen Announces Fourth Quarter and Full Year 2018 Financial Results and Provides 2019 Outlook

    BOULDER, Colo., March 13, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial and operating results for the fourth quarter and full-year ended December 31, 2018. “We are encouraged by the advances our team has made in the development of microRNA targeted therapies in 2018 and pleased to begin 2019 with three clinical stage product candidates being evaluated in five clinical trials for the potential to treat patients who suffer from a variety of diseases with high unmet medical need.” said William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen Therapeutics. “In addition to the release of encouraging clinical data for cobomarsen in cutaneous T-cell lymphoma (CTCL), we have also seen exciting preliminary clinical activity for cobomarsen in other blood cancers and have also advanced the development of remlarsen into a Phase 2 clinical trial in cutaneous fibrosis.

  • GlobeNewswire

    miRagen Therapeutics to Present a Corporate Overview at the 29th Annual Oppenheimer & Co. Healthcare Conference

    BOULDER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Oppenheimer & Co. 29th Annual Healthcare Conference, taking place March 19-20 in New York City.

  • GlobeNewswire

    miRagen Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results and Host a Conference Call on March 13th

    BOULDER, Colo., Feb. 20, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year ended December 31, 2018. The call will also be webcast and can be accessed from the Investors and Media section of the Company’s website at www.miragen.com.  A replay of this conference call will be available on miRagen’s website approximately one hour after the event.

  • GlobeNewswire

    miRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen

    50% of cutaneous T-cell lymphoma patients treated with 300mg IV infusion achieved objective response lasting for greater than four months (ORR4)Evidence of disease stabilization.

  • GlobeNewswire

    miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum

    BOULDER, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it will present new data from its Phase 1 trial of cobomarsen in HTLV-1 associated adult T-cell leukemia/lymphoma (ATLL) as well as its Phase 1 trial of cobomarsen in patients with mycosis fungoides, the most common form of cutaneous T-cell (CTCL) at the 11th Annual T-Cell Lymphoma Forum, which is being held in La Jolla, CA, from January 10th-12th.